UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
☒Quarterly Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
For the Quarterly Period Ended SeptemberJune 30, 20152016
☐Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
For the Transition Period from ______ to _______.

Commission File No. 000-20970

COGENTIX MEDICAL, INC.
(Exact name of registrant as specified in its Charter)

Minnesota, U.S.A.13-3430173
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

5420 Feltl Road
Minnetonka, Minnesota,  55343
(Address of principal executive offices)

(952) 426-6140
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES ☒  NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  YES ☒  NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer ☐
Accelerated Filer ☐Non-Accelerated Filer ☐Smaller Reporting Company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)
YES ☐   NO ☒

As of November 6, 2015August 10, 2016 the registrant had 26,058,23526,144,299 shares of common stock outstanding.
 
Table of Contents
INDEX

COGENTIX MEDICAL, INC. AND SUBSIDIARIES

PART I. FINANCIAL INFORMATION 
  
Item 1.
Financial Statements
 
   
  
Condensed Consolidated Balance Sheets
5
   
  
Condensed Consolidated Statements of Operations
7
   
  
Condensed Consolidated Statements of Comprehensive Loss
8
   
  
Condensed Consolidated Statement of Shareholders’ Equity
9
   
  
Condensed Consolidated Statements of Cash Flows
10
   
  
Notes to the Condensed Consolidated Financial Statements
11
   
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
20
   
Item 3.
Quantitative and Qualitative Disclosures about Market Risk
2526
   
Item 4.
Controls and Procedures
2526
  
PART II. OTHER INFORMATION 
  
Item 1.
Legal Proceedings
2526
   
Item 1A.
Risk Factors
2627
   
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
2627
   
Item 3.
Defaults upon Senior Securities
2627
   
Item 4.
Mine Safety Disclosures
2627
   
Item 5.
Other Information
2627
   
Item 6.
Exhibits
2627
   
  
SIGNATURES
2729
   
  Certification by the Chief Executive Officer and the Chief Financial OfficerPEO pursuant to Section 302 
   
  Certification by the Chief Executive Officer andPFO pursuant to Section 302
Certification by the Chief Financial OfficerPEO pursuant to Section 906
Certification by the PFO pursuant to Section 906 
 
Page 2
Table of Contents
As used in this report, the terms “Cogentix,””Cogentix “Cogentix Medical,” “Company,” “we,” “us,” “our” and similar references refer to Cogentix Medical, Inc. (formerly known as Vision-Sciences, Inc.) and our consolidated subsidiaries, and the term “common stock” refers to our common stock, par value $0.01 per share.  References to “VSCI,” “Vision-Sciences” or “Vision” generally refer to Vision-Sciences, Inc. and its consolidated subsidiaries prior to the consummation of the merger of Uroplasty, Inc. with and into Vision’s wholly-owned merger subsidiary (“Merger Sub”) on March 31, 2015 (the “Merger”), and sometimes also are used as references to our current, ongoing operations related to the historical VSCI that continue following the Merger.  References to “UPI” or “Uroplasty” generally refer to Uroplasty, Inc., and its consolidated subsidiaries prior to the consummation of the Merger, and sometimes also are used as reference to our current, ongoing operations related to the historical Uroplasty that continuescontinue following the Merger.

All share and per share amounts have been adjusted to reflect the one-for-five reverse split of Vision’s outstanding common stock effective on March 31, 2015 immediately prior to the effective time of the Merger.  All numbers and prices related to common shares and options of Uroplasty that predated the Merger have been adjusted to reflect the exchange ratio of 3.6331 shares of our common stock for each share of Uroplasty common stock, as well as the above mentioned one-for-five reverse stock split, a combined impact of 0.72662 shares of our common stock for each Uroplasty share of common stock.

This report contains the following trademarks, trade names and service marks of ours: PrimeSightTM, Vision-Sciences®, EndoSheath®, Slide-On®, EndoWipe®, and The Vision System®, for our endoscopy products,and Urgent PC® for our neuromodulation product, Macroplastique® Implants for our urological tissue bulking products,product, VOX® for our otolaryngology tissue bulking products, PTQ® for our colorectal tissue bulking and Uroplasty® for Uroplasty, LLC, one of our subsidiaries.  This report also contains trademarks, trade names andservice marks that are owned by other persons or entities.
 
We changed our fiscal year from a fiscal year ending on March 31 of each year to a fiscal year ending on December 31 of each year effective as of December 31, 2015. This action created a transition period of April 1, 2015 through December 31, 2015 (the “Transition Period”).  Unless otherwise indicated herein, comparisons of fiscal year results or fiscal quarter results in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” portion of this Report, and elsewhere herein, compare results for the three-month unaudited period from April 1, 2016 through June 30, 2016 to the three-month unaudited period from April 1, 2015 through June 30, 2015, and the six month unaudited period from January 1, 2016 through June 30, 2016 to the six month unaudited period from January 1, 2015 through June 30, 2015.  As a result of the Merger, our financial statements prior to March 31, 2015 are the historical financial statements of Uroplasty, and our financial statements on or after March 31, 2015 reflect the results of the operations of Uroplasty and Vision-Sciences on a combined basis.

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Statements contained in this report that refer to our estimated or anticipated future results, including estimated synergies, or other non-historical facts are forward-looking statements that reflect our current perspective of existing trends and information as of the date of this report.  Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions.  These forward-looking statements are based on current expectations about future events affecting us and are subject to uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially from those matters expressed or implied by our forward-looking statements.  Forward-looking statements (including oral representations) are only predictions or statements of current plans and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties.  By way of example and without implied limitation, such risks, uncertainties and factors that affect our business included:

·we may obtain additional financing, which may not be available on favorable terms at the time it is needed and which could reduce our operational and strategic flexibility;
·we may be unable to successfully integrate Uroplasty’s and Vision’s operations or realize the anticipated cost savings and other potential benefit of the merger in a timely manner, if at all. As a result, the value of our shares may be adversely affected;
·we may attempt to acquire new products or technologies, and if we are unable to successfully complete these acquisitions or to integrate acquired businesses, products, technologies or employees, we may fail to realize expected benefit or harm our existing business;
·we continue to incur losses and may never reach profitability;
Page 3
Table of Contents
·the use and acceptance of our products depends heavily upon the availability of third-party reimbursement for the procedures in which its products are used;
·we cannot predict how quickly or how broadly the market will accept our products;
·that we are subject to changing federal and state regulations that could increase the cost of doing business or impose requirements with which we cannot comply;
·the 2010 Healthcare Reform Legislation imposes an excise tax on us that we may be unable to recoup, and requires cost controls that may impact the rate of reimbursement for our products;
·changes in regulatory policy, particularly at the FDA, might adversely affect our operations;
·if we are not able to attract, retain and motivate our sales force and expand our distribution channels, our sales and revenues will suffer;
Page 3
Table of Contents
·the size and resources of our competitors may render it difficult for us to successfully compete in the marketplace;
·we are primarily dependent on sales from a limited number of product lines and our business would suffer if sales of any of these product lines decline;
·we could be subject to fines and penalties, or required to temporarily or permanently cease offering products, if we fail to comply with the extensive regulations applicable to the sale and manufacture of medical products;
·our distributors may not obtain regulatory approvals in a timely basis, or at all;
·we may not have the resources to successfully market our products, which would adversely affect our business and results of operations;
·if we cannot attract and retain our key personnel and management team, we may not be able to manage and operate successfully, and we may not be able to meet our strategic objectives;
·if third parties claim that we infringe upon their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling the affected product;
·if we are unable to adequately protect our intellectual property rights, we may not be able to compete effectively;
·product liability claims could adversely affect our business and results of operations;
·security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer;
·the loss or interruption of materials from any of our key suppliers could delay the manufacture of our products, which would limit our ability to generate sales and revenues;
·if we are not able to maintain sufficient quality controls, regulatory approvals of our products by the European Union, Canada, the FDA or other relevant authorities could be delayed or denied and our sales and revenues will suffer;
·if we are not able to acquire or license other products, our business and future growth prospects could suffer;
·our business strategy relies on assumptions about the market for our products, which, if incorrect, would adversely affect our business prospects and profitability;
·we derive a significant portion of our sales and revenues from outside of the U.S. and we are subject to the risks of international operations;
·failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to, among other things, penalties and legal expenses that could harm our reputation and have a material adverse effect on our business, financial condition and operating results;
·our stock is thinly traded and you may find it difficult to sell your investment in our stock at quoted prices;
·our stock price may fluctuate and be volatile;
·future sales of our common stock in the public market could lower our share price;
·our corporate documents contain provisions that could discourage, delay or prevent a change in control of the company; and
·we do not intend to declare dividends on our stock in the foreseeable future.

When relying on forward-looking statements to make decisions with respect to the Company, our investors and others should carefully consider the foregoing factors and other uncertainties and potential events and read our filings with the SEC, available at www.sec.gov for a discussion of these and other risks and uncertainties.  We do not undertake any obligation to update or revise any forward-looking statement, except as may be required by law.  We qualify all forward-looking statements by these cautionary statements.
 
Page 4
Table of Contents
PART I.FINANCIAL INFORMATION
ITEM 1.
FINANCIAL STATEMENTS

COGENTIX MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

 
September 30, 2015
(Unaudited)
  
 
March 31, 2015
  June 30, 2016  December 31, 2015 
          
Assets          
    
Current assets:          
Cash and cash equivalents $2,928,694  $9,261,903  $2,867,080  $1,976,594 
Accounts receivable, net  6,497,912   7,306,653   6,481,899   8,191,391 
Inventories  4,963,630   4,825,984   5,680,959   4,584,844 
Other  1,636,371   749,466   774,054   834,076 
Total current assets  16,026,607   22,144,006   15,803,992   15,586,905 
                
Property, plant, and equipment, net  2,605,934   1,813,343   2,305,452   2,554,822 
Goodwill  18,749,888   18,749,888   18,749,888   18,749,888 
Other intangible assets, net  12,480,200   13,748,582   10,664,294   11,846,009 
Deferred tax assets and other  309,211   296,860   289,109   269,121 
        
Total assets $50,171,840  $56,752,679  $47,812,735  $49,006,745 

See accompanying notes to the Condensed Consolidated Financial Statements.
 
Page 5
Table of Contents
COGENTIX MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
September 30, 2015
(Unaudited)
  
 
March 31, 2015
  June 30, 2016  December 31, 2015 
          
Liabilities and Shareholders’ Equity          
          
Current liabilities:          
Accounts payable $3,318,159  $3,967,975  $2,312,809  $2,209,473 
Interest payable  676,165   523,743 
Income taxes payable  31,628   25,998   33,554   20,866 
Accrued liabilities:                
Compensation  2,806,252   3,285,952   4,338,519   3,281,809 
Deferred revenue  517,045   307,936 
Other  1,052,179   2,450,058   763,654   641,561 
Total current liabilities  7,884,383   10,253,726   7,965,581   6,461,645 
                
Convertible debt – related party, net  23,064,570   22,529,497   23,891,101   23,336,854 
Interest payable  935,974   757,615 
Accrued pension liability  998,829   955,780   734,541   663,071 
Deferred rent  644,952   -   656,733   671,088 
Other  113,579   265,766   154,010   157,453 
                
Total liabilities  32,706,313   34,004,769   34,337,940   32,047,726 
                
Commitments and contingencies  -   - 
        
Shareholders’ equity:                
Preferred stock, $0.01 par value 5,000,000 Shares authorized; none issued or outstanding  -   -   -   - 
Common stock $.01 par value; 100,000,000 shares authorized, 26,058,235 and 25,676,212 shares issued and outstanding at September 30, 2015 and March 31, 2015, respectively
  260,583   256,763 
Common stock $.01 par value; 100,000,000 shares authorized, 26,044,299 and 26,057,327 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively
  260,445   260,574 
Additional paid-in capital  76,146,738   75,530,641   76,653,435   76,485,650 
Accumulated deficit  (57,820,629)  (51,883,229)  (62,541,882)  (58,910,707)
Accumulated other comprehensive loss  (1,121,165)  (1,156,265)  (897,203)  (876,498)
                
Total shareholders’ equity  17,465,527   22,747,910   13,474,795   16,959,019 
                
Total liabilities and shareholders’ equity $50,171,840  $56,752,679  $47,812,735  $49,006,745 

See accompanying notes to the Condensed Consolidated Financial Statements.
 
Page 6
Table of Contents
COGENTIX MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

 
Three Months Ended
June 30,
  
Six Months Ended
June 30,
 
 
Three Months Ended
September 30
  
Six Months Ended
September 30
  2016  2015  2016  2015 
 2015  2014  2015  2014             
                    
Net sales $11,834,187  $6,454,630  $22,984,399  $12,839,259  $13,004,651  $11,150,212  $25,211,215  $18,170,023 
Cost of goods sold  3,953,940   753,225   7,606,845   1,544,536   4,087,165   3,652,510   7,888,359   4,454,278 
                                
Gross profit  7,880,247   5,701,405   15,377,554   11,294,723   8,917,486   7,497,702   17,322,856   13,715,745 
                                
Operating expenses                                
General and administrative  1,935,286   1,288,297   3,828,559   2,865,665   1,867,312   1,893,272   3,529,781   3,295,644 
Research and development  1,035,253   651,035   2,097,712   1,560,479   1,100,056   1,062,459   2,036,934   1,671,763 
Selling and marketing  5,845,798   4,818,704   12,496,942   10,091,325   5,433,439   6,651,380   11,069,201   11,596,495 
Amortization  634,191   8,226   1,268,382   16,552 
Amortization of intangibles  590,858   634,191   1,181,716   641,453 
Proxy settlement costs  2,177,990   -   2,311,541   - 
Merger related costs  437,252   -   905,699   -   -   468,607   -   2,046,773 
  9,887,780   6,766,262   20,597,294   14,534,021   11,169,655   10,709,909   20,129,173   19,252,128 
                                
Operating loss  (2,007,533)  (1,064,857)  (5,219,740)  (3,239,298)  (2,252,169)  (3,212,207)  (2,806,317)  (5,536,383)
                                
Other income (expense)                                
Interest income (expense)  (352,423)  1,833   (694,396)  4,845 
Interest income  170   1,582   405   3,440 
Interest expense  (376,363)  (343,555)  (766,667)  (343,794)
Foreign currency exchange gain (loss)  1,847   (2,190)  4,846   (1,279)  (17,844)  2,998   (25,406)  2,034 
  (350,576)  (357)  (689,550)  3,566   (394,037)  (338,975)  (791,668)  (338,320)
                                
Loss before income taxes  (2,358,109)  (1,065,214)  (5,909,290)  (3,235,732)  (2,646,206)  (3,551,182)  (3,597,985)  (5,874,703)
                                
Income tax expense  10,532   15,032   28,110   34,847   18,561   17,578   33,190   27,298 
                                
Net loss $(2,368,641) $(1,080,246) $(5,937,400) $(3,270,579) $(2,664,767) $(3,568,760) $(3,631,175) $(5,902,001)
                                
Basic and diluted net loss per common share $(0.09) $(0.07) $(0.23) $(0.21) $(0.10) $(0.14) $(0.14) $(0.28)
                                
Weighted average common shares outstanding:                                
Basic and diluted  25,410,646   15,707,835   25,377,047   15,763,286   25,518,330   25,437,860   25,446,765   20,772,399 

See accompanying notes to the Condensed Consolidated Financial Statements.
 
Page 7
Table of Contents
COGENTIX MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)

 
Three Months Ended
September 30
  
Six Months Ended
September 30
  
Three Months Ended
June 30
  
Six Months Ended
June 30
 
 2015  2014  2015  2014  2016  2015  2016  2015 
                    
Net loss $(2,368,641) $(1,080,246) $(5,937,400) $(3,270,579) $(2,664,767) $(3,568,760) $(3,631,175) $(5,902,001)
Other comprehensive income (loss), net of tax:                                
Foreign currency translation adjustments  (859)  (135,688)  56,599   (136,477)  (50,278)  57,457   (24,622)  (122,302)
Unrealized loss on available-for-sale investments  -   (32)  -   (775)
Pension adjustments  254   25,382   (21,499)  24,986   12,491   (21,752)  3,917   (331,990)
                
Total other comprehensive income (loss), net of tax  (605)  (110,338)  35,100   (112,266)  (37,787)  35,705   (20,705)  (454,292)
                
Comprehensive loss $(2,369,246) $(1,190,584) $(5,902,300) $(3,382,845) $(2,702,554) $(3,533,055) $(3,651,880) $(6,356,293)

See accompanying notes to the Condensed Consolidated Financial Statements.
 
Page 8
Table of Contents
COGENTIX MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

Six Months Ended SeptemberJune 30, 20152016
(Unaudited)

  
 
 
Common Stock
  
 
Additional
Paid-in
  
 
 
Accumulated
  
Accumulated
Other
Comprehensive
  
 
Total
Shareholders'
 
  Shares  Amount  Capital  Deficit  Income (Loss)  Equity 
             
Balance at March 31, 2015  25,676,212  $256,763  $75,530,641  $(51,883,229) $(1,156,265) $22,747,910 
                         
Share-based compensation  492,430   4,924   635,125   -   -   640,049 
                         
Payment of income tax from vested restricted stock  (110,407)  (1,104)  (19,028)  -   -   (20,132)
                         
Comprehensive income (loss)  -   -   -   (5,937,400)  35,100   (5,902,300)
                         
Balance at September 30, 2015  26,058,235  $260,583  $76,146,738  $(57,820,629) $(1,121,165) $17,465,527 
              Common Stock       
Additional
Paid-in
Capital
        
Accumulated
Deficit
      
Accumulated
Other
Comprehensive
Income (Loss)
       
Total
Shareholders'
Equity
   
  Shares  Amount         
                   
Balance at December 31, 2015  26,057,327  $260,574  $76,485,650  $(58,910,707) $(876,498) $16,959,019 
                         
Share-based compensation  42,170   423   224,576   -   -   224,999 
                         
Payment of income tax from vested restricted stock  (55,198)  (552)  (56,791)          (57,343)
                         
Comprehensive loss  -   -   -   (3,631,175)  (20,705)  (3,651,880)
                         
Balance at June 30, 2016  26,044,299  $260,445  $76,653,435  $(62,541,882) $(897,203) $13,474,795 

See accompanying notes to the Condensed Consolidated Financial Statements.
 
Page 9
Table of Contents
COGENTIX MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 
Six Months Ended
September 30
  
Six Months Ended
June 30,
 
 2015  2014  2016  2015 
Cash flows from operating activities:          
Net loss $(5,937,400) $(3,270,579) $(3,631,175) $(5,902,001)
Adjustments to reconcile net loss to net cash used in operating activities:        
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:        
Depreciation and amortization  1,704,914   139,252   1,590,903   925,107 
Loss on disposal of equipment  4,859   834   -   38,668 
Amortization of premium on marketable securities  -   311 
Share-based compensation expense  640,049   660,891   224,999   536,439 
Amortization of discount on related party debt  535,073   -   554,247   265,967 
Long term incentive plan  (105,770)  -   (46,870)  (8,491)
Tax expense (benefit)  (5,382)  1,973 
Tax benefit  (1,161)  (89,945)
Deferred rent  616,375   23,150   9,895   (2,263)
Payments of income tax from vested restricted stock  (20,132)  - 
Proceeds from restricted stock exchanged for taxes  (57,343)  - 
Changes in operating assets and liabilities:                
Accounts receivable, net  53,299   155,498   1,691,231   258,291 
Inventories  (134,743)  (10,822)  (1,096,308)  23,025 
Other current assets  (103,915)  (18,093)  68,790   22,829 
Accounts payable  104,130   (153,490)
Interest payable  152,422   -   178,359   76,211 
Accounts payable  (647,275)  (230,103)
Accrued compensation  (482,808)  113,132   1,059,496   2,306 
Accrued liabilities, other  (1,467,229)  (5,669)  118,912   (301,580)
Accrued pension liability  9,190   (35,524)  42,862   174,014 
Deferred revenue  47,707   -   250,679   72,080 
Net cash used in operating activities  (5,140,766)  (2,475,749)
Net cash provided by (used in) operating activities  1,061,646   (4,062,833)
                
Cash flows from investing activities:                
Proceeds from maturity of available-for-sale investments  -   3,450,000 
Cash acquired from merger with Vision-Sciences  -   2,019,610 
Purchases of property, plant and equipment  (1,216,962)  (128,041)  (166,976)  (609,615)
Proceeds from sale of property, plant and equipment  (120)  1,552   -   999 
Net cash (used in) provided by investing activities  (1,217,082)  3,323,511   (166,976)  1,410,994 
                
Cash flows from financing activities:        
Proceeds from exercise of stock options  -   67,850 
Net cash provided by financing activities  -   67,850   -   - 
                
Effect of exchange rate changes on cash and cash equivalents  24,639   (57,053)
Effect of exchange rates on cash and cash equivalents  (4,184)  (55,705)
                
Net (decrease) increase in cash and cash equivalents  (6,333,209)  858,559 
Net increase (decrease) in cash and cash equivalents  890,486   (2,707,544)
                
Cash and cash equivalents at beginning of period  9,261,903   8,681,609   1,976,594   8,703,790 
                
Cash and cash equivalents at end of period $2,928,694  $9,540,168  $2,867,080  $5,996,246 
                
Cash paid during the period for income taxes $16,672  $42,715 
Supplemental disclosure of cash flow information:        
Cash paid during the period for income tax $19,378  $17,578 
Cash paid during the period for interest $7,975  $-  $34,061  $1,400 

See accompanying notes to the Condensed Consolidated Financial Statements.Statements.
 
Page 10
Table of Contents
COGENTIX MEDICAL, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 1.Summary of Significant Accounting Policies

Basis of Presentation

Cogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company. We design, develop, manufacture and market innovative proprietary technologies servinga robust line of high performance fiberoptic and video endoscopy products under the urology, urogynecology/gyn, ENT (ear, nosePrimeSightTM brand that are used across multiple surgical specialties in diagnostic and throat) and gastrointestinal markets. The Urgent® PC Neuromodulation System delivers percutaneous tibial nerve stimulation (PTNS) which has FDA clearance for the office-based treatment of overactive bladder (OAB) and has regulatory approvals for the treatment of OAB and fecal incontinence (FI) in various international markets.procedures. The FDA-cleared and CE marked EndoSheath®PrimeSight Endoscopy Systems and EndoSheath Protective Barrier combine state-of-the-art endoscopic technology with a sterile, disposable microbial barrier, providing practitioners and healthcare facilities with a solution to meet the growing need for safe, efficient and cost-effective flexible endoscopy.  We also offer the Urgent® PC Neuromodulation System, a device that delivers percutaneous tibial nerve stimulation (“PTNS”), for the office-based treatment of overactive bladder (“OAB”).  The Urgent® PC Neuromodulation System has FDA clearance in the United States and has regulatory approvals for the treatment of OAB and fecal incontinence (FI) in various international markets. The Company also offers Macroplastique®, a urethral bulking agent for the treatment of stress urinary incontinence. Outside the U.S., the Company markets additional bulking agents: PTQ® for the treatment of fecal incontinence and VOX® for vocal cord augmentation and vesicourethral reflux.

The Company is the result of the Merger effective as of March 31, 2015, of two medical device companies, Uroplasty, Inc. (“UPI”) and Vision-Sciences, Inc. (“VSCI”).  On the effective date of the Merger, the two companies completed an all-stock merger, pursuant to which UPI merged with and into Merger Sub.  Merger Sub, wasa wholly owned subsidiary of VSCI.   VSCI continued to be the sole member of the surviving company fromcompany.  After the Merger, andmerger, VSCI changed its name to Uroplasty, LLC.   After the merger, VSCI and its consolidated subsidiaries, including Uroplasty, LLC, and its subsidiaries, operate under the name Cogentix Medical, Inc.

Upon closing of the Merger, the former UPI stockholders owned approximately 62.5% and the VSCI shareholders retained approximately 37.5% of the Company. Accordingly, while VSCI was the legal acquirer and issued its shares in the Merger, UPI is the acquiring company in the Merger for accounting purposes and the Merger has been accounted for as a reverse acquisition under the acquisition method of accounting for business combinations. As a result, the financial statements of the Company prior to the effective date of the Merger are the historical financial statements of UPI, whereas the financial statements of the Company after the effective date of the Merger reflect the results of the operations of UPI and VSCI on a combined basis. See additional disclosure provided in noteNote 2.
 
All share amounts and price per share amounts for all periods presented relate to VSCI shares with UPI shares and price per share converted to VSCI amounts based on the conversion ratio in the acquisition agreement and the one for five reverse stock split that occurred on March 31, 2015.

We have prepared our Condensed Consolidated Financial Statements included in this quarterly report on Form 10-Q, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, have been condensed or omitted, pursuant to such rules and regulations, although we believe that our disclosures are adequate to make the information not misleading.  The consolidated results of operations for any interim period are not necessarily indicative of results for a full fiscal year.  These Condensed Consolidated Financial Statements, presented herein, should be read in conjunction with the audited consolidated financial statements and related notes included in our annual report on Form 10-K10-KT for the fiscal yearnine-months ended MarchDecember 31, 2015.

The Condensed Consolidated Financial Statements presented herein as of SeptemberJune 30, 20152016 and for the three-three and six-monthsix month periods ended SeptemberJune 30, 20152016 and 2014,2015, reflect, in the opinion of management, all material adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the consolidated financial condition, results of operations and cash flows for the interim periods.

We have identified certain accounting policies that we consider particularly important for the portrayal of our results of operations and financial condition and which may require the application of a higher level of judgment by our management, and as a result are subject to an inherent level of uncertainty.  These are characterized as “critical accounting policies” and address revenue recognition, accounts receivable, valuation of inventory, foreign currency translation/transactions, purchase price allocation on acquisition, the determination of recoverability of long-lived and intangible assets, long-term incentive plans, share-based compensation, defined benefit pension plans and income taxes, each of which is described in our annual report on Form 10-K10-KT for the fiscal yearnine-months ended MarchDecember 31, 2015.  Based upon our review, we have determined that these policies remain our most critical accounting policies for the six months ended SeptemberJune 30, 20152016 and we have made no changes to these policies since March 31, 2015.during 2016.
 
Page 11
Table of Contents
Liquidity and Capital Resources

We have incurred substantial operating losses since our inception.  We anticipate that we will incur negative cash flows from operations during fiscal 2016, driven by continued investment in a direct sales force for the U.S. market, spending for marketing and for research and development, integration of UPI and VSCI, and general business operations. As of SeptemberJune 30, 2015,2016, we had cash and cash equivalents totaling approximately $2.9 million. On September 18, 2015, we entered into a $7.0 million line of credit with Venture Bank to provide non-dilutive resources to execute management’s growth strategies for the EndoSheathPrimeSightTM and Urgent® PC product lines and for general corporate purposes. Note 6 contains further information regarding the line of credit.  If operations do not generate sufficient cash in the future and if we were to seek additional financing, there can be no assurance that any such additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.

Note 2.Business Combination - Merger Between Uroplasty, Inc. and Vision-Sciences, Inc.

The Merger has been accounted for as an acquisition of VSCI by UPI, in accordance with Accounting Standards Codification (ASC) Topic 805, "Business Combinations," using the acquisition method of accounting with UPI as the accounting acquirer. Since the Company (formerly known as Vision-Sciences), as the parent company of UPI after the Merger, is the legal acquirer, the Merger has been accounted for as a reverse acquisition.  Under these accounting standards, UPI’s total purchase price of $16.5 million is calculated as if UPI had issued its shares to VSCI stockholders and converted options and warrants to purchase VSCI shares to options and warrants to purchase UPI’s common stock.

Under the acquisition method of accounting, the total purchase price was allocated to the net tangible and intangible assets of VSCI acquired in the Merger, based on their fair values at the effective date of the Merger. The estimated fair values are preliminary and based on the information thatallocation was available as of the effective date of the Merger. The Company believes that the information provides a reasonable basis for estimating the fair values, but the Company is waiting for additional information necessary to finalize these amounts, particularly with respect to the estimated fair value of intangible assets and property, plant and equipment and deferred taxes related thereto. Thus the preliminary measurements of fair value reflected are subject to changes and such changes could be significant. The Company expects to finalize the valuation and complete the purchase price allocation as soon as practicable, but no later than one year from the effective date of the Merger. There were no changes during the six months ended September 30, 2015finalized without any change to the preliminary measurements of fair value. The preliminary allocation of the purchase price to assets acquired and liabilities assumed is as follows:

Cash and cash equivalents $2,020,000 
Accounts receivable  4,249,000 
Inventories  4,462,000 
Other current assets  369,000 
Property, plant and equipment  817,000 
Goodwill  18,750,000 
Other intangibles  13,660,000 
Other non-current assets  97,000 
Total assets acquired  44,424,000 
     
Accounts payable and other liabilities  5,209,000 
Deferred revenue  176,000 
Convertible debt – related party  22,530,000 
Other non-current liabilities  40,000 
Total liabilities assumed  27,955,000 
     
Total purchase price $16,469,000 

The allocation of the purchase price to the net assets acquired and liabilities assumed resulted in the recognition of the following intangible assets:

  Amount  Weighted Average Life-Years 
Developed technology $6,200,000   7 
Customer relationships  7,270,000   5 
Trade names  190,000   10 
  $13,660,000     
 
Page 12
Table of Contents
The supplemental unaudited pro forma net sales and net loss of the combined entity had the acquisition been completed on AprilJanuary 1, 2013:2015:

 
Three months ended
September 30,
2014
  
Six months ended
September 30,
2014
  
Six months
ended
June 30,
2015
(unaudited)
 
       
Supplemental pro forma combined results of operations:       
Net sales $10,564,630  $20,701,259  $23,835,350 
Net loss $(2,623,246) $(6,790,579) $(10,264,196)
Loss per share – basic and diluted $(0.14) $(0.34)
Net loss per share – basic and diluted $(0.40)

Adjustments to the supplemental pro forma combined results of operations are as follows:

 
Three months ended
September 30,
2014
  
Six months ended
September 30,
2014
  
Six months ended
June 30,
2015
 
       
Increase in amortization of intangibles $279,000  $561,000  $510,000 
Interest amortization on related party debt  594,000   1,189,000   279,000 
Increase in net loss $873,000  $1,750,000  $789,000 

These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the AprilJanuary 1, 2013,2015 or of future results of the consolidated entities.  The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the acquisition.

Note 3.Goodwill and Other Intangible Assets

Goodwill

As described in noteNote 2, on March 31, 2015, for accounting purposes, UPI was deemed to have acquired VSCI for a purchase price of $16.5 million, and as a result, the Company recognized $18.8 million in goodwill. There was no change in the goodwill balance as of SeptemberJune 30, 2015.2016.

Other Intangible Assets

Other intangible assets consisted of the following at SeptemberJune 30, 20152016 and MarchDecember 31 2015:

 September 30, 2015  March 31, 2015  June 30, 2016  December 31, 2015 
 
Gross
Carrying
Amount
  
 
Accumulated
Amortization
  
Gross
Carrying
Amount
  
 
Accumulated
Amortization
  
Gross
Carrying
Amount
  
Accumulated
Amortization
  
Gross
Carrying
Amount
  
Accumulated
Amortization
 
Developed technology $6,200,000  $443,000  $6,200,000  $-  $6,200,000  $1,107,000  $6,200,000  $664,000 
Patents  5,653,000   5,579,000   5,653,000   5,564,000   5,653,000   5,601,000   5,653,000   5,586,000 
Trademarks and trade names  190,000   44,000   190,000   -   190,000   71,000   190,000   67,000 
Customer relationships  7,270,000   767,000   7,270,000   -   7,270,000   1,870,000   7,270,000   1,150,000 
 $19,313,000  $6,833,000  $19,313,000  $5,564,000  $19,313,000  $8,649,000  $19,313,000  $7,467,000 
Accumulated amortization  6,833,000       5,564,000       8,649,000       7,467,000     
                                
Net book value of amortizable intangible assets $12,480,000      $13,749,000      $10,664,000      $11,846,000     
Page 13
Table of Contents

For the six months ended September 30,June, 2016 and 2015, and 2014, amortization of intangible assets charged to operations was approximately $1,268,000$1,182,000 and $17,000,$641,000, respectively.  The weighted average remaining amortization period for intangible assets as of SeptemberJune 30, 20152016 was approximately 5.484.73 years.

Page 13
Table of Contents
Note 4.
4.		Newly AdoptedNew Accounting Pronouncements

In September 2015,March 2016, the Financial Accounting Standards Board (FASB)(“FASB”) issued Accounting Standards Update (ASU)(“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. This new standard is effective for annual periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption is permitted in any interim or annual period, with adjustments reflected as of the beginning of the fiscal year of adoption. We are evaluating the effect that this guidance will have on our consolidated financial statements and related disclosures.
In February 2016, FASB issued ASU 2016-2, Leases, under which lessees will recognize most leases on-balance sheet. This will generally increase reported assets and liabilities. For public entities, this ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2018. ASU 2016-2 mandates a modified retrospective transition method for all entities. The Company will begin the process of determining the impact this ASU will have on the Company’s consolidated financial statements.
In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which amends the guidance requiring companies to separate deferred income tax liabilities and assets into current and non-current amounts in a classified statement of financial position. This accounting guidance simplifies the presentation of deferred income taxes, such that deferred tax liabilities and assets be classified as non-current in a classified statement of financial position. This accounting guidance is effective for the Company beginning in the first quarter of 2017.  We do not believe the adoption of this update will have a material impact on our consolidated financial statements.
In September 2015, the FASB issued ASU No. 2015-16, “Business Combinations (Topic 805).”  The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined.  Under the new guidance, the acquirer should record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date.  On the face of the income statement or in the notes, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods need to be reflected as if the adjustment to the provisional amounts had been recognized as of the acquisition date.  The amendments in ASU No. 2016-16 are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.  We do not believe the adoption of this update will have a material impact on our financial statements.

In July 2015, the FASB issued ASU No. 2015-12, “Plan Accounting: Defined Benefit Pension Plans (Topic 815).”    Under the new guidance, plans are no longer required to measure fully benefit-responsive investment contracts (FBRICs) at fair value, disaggregate investments by nature, risks and characteristics, disclose individual investments that represent five percent or more of net assets available for benefits, or disclose net appreciation or depreciation for investments by general price. The amendments in ASU No. 2015-12 are effective for fiscal years beginning after December 15, 2015 and earlier adoption is permitted.  We are still evaluating whether ordo not believe the adoption of this update is applicable towill have a material impact on our business.financial statements.

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory (Topic 330).”  Under the current guidance (i.e., ASC 330-10-352 before the ASU), an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor).  The new guidance requires entities to measure most inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures). The ASU will not apply to inventories that are measured by using either the last-in, first-out (LIFO) method or the retail inventory method (RIM).  The amendments in ASU No. 2015-11 are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.  We do not believe the adoption of this update will have a material impact on our financial statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).”  The guidance in this update supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition.”  In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (for example, assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this update.  Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The amendments in ASU No. 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early application is permitted for annual reporting periods beginning after December 31, 2016.  We are still evaluating whether or not this update is applicable to our business.

Page 14
Table of Contents
Note 5.Fair Value Measurements

Estimates of fair value for financial assets and liabilities are based on the framework established in the accounting guidance for fair value measurements.  The framework defines fair value, provides guidance for measuring fair value and requires certain disclosures.  The framework prioritizes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  The following three broad levels of inputs may be used to measure fair value under the fair value hierarchy:
 
·Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
 
·Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.  These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
 
Page 14
Table of Contents
·Level 3: Significant unobservable inputs that cannot be corroborated by observable market data and reflect the use of significant management judgment.  These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions.
 
If the inputs used to measure the financial assets and liabilities fall within more than one of the different levels described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

On SeptemberJune 30, 20152016 and MarchDecember 31, 2015, the only asset or liability measured at fair value on a recurring basis was the long-term incentive plan accrual with a fair value of $113,000$29,600 and $730,000,$130,000, respectively, considered a level 3 measurement. The long-term incentive plan began on October 2, 2014 and is described in noteNote 9. The estimated fair value of the accrual is calculated on a quarterly basis using a Monte Carlo valuation model.  Vesting is based on the probability of meeting the stock price criteria, the probability of which is considered in determining the estimated fair value.

Remeasurements to fair value on a nonrecurring basis relate primarily to our property, plant and equipment and intangible assets and occur when the derived fair value is below their carrying value on our Consolidated Balance Sheet.  As of SeptemberJune 30, 20152016 and MarchDecember 31, 2015 we had no remeasurements of such assets to fair value.

The carrying amounts reported in the Condensed Consolidated Balance Sheets for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued liabilities and convertible debt-related party approximate fair market value.

Note 6.Line of Credit

On September 18, 2015, we entered into a loan agreement with Venture Bank, a Minnesota banking corporation, providing us with a committed $7 million secured revolving credit facility (“Facility”), subject to eligible accounts receivable and inventory.  The Facility will expire on March 18, 2017 and any loans outstanding on such date will mature and become payable.  The Facility is secured by substantially all of our assets.
 
Under the Facility, we may borrow the lesser of:  (a) the sum of (i) eighty percent (80%) of the value of eligible accounts receivable; and (ii) forty percent (40%) of the value of eligible inventory capped at the lesser of (1) $2 million or (2) fifty percent (50%) of the Notes principal balance outstanding; or (b) $7 million.  As of SeptemberJune 30, 2015,2016, based on eligible receivables and inventory, our total available borrowing base was $4,828,000.$5,366,000.  We did not have any borrowings under the facilityFacility as of SeptemberJune 30, 2015.2016.
 
Loans under the Facility bear interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 2.25%, provided that in no case will the interest charged be less than 5.5%.  In the event that there is an event of default under the Facility, the interest rate will be increased by 6.0% for the entire period that an event of default exists.  In addition, the Borrowers will pay a non-usage fee of 0.25% based on the average unused and available portion of the Facility on a monthly basis.
 
Page 15
Table of Contents
Note 7.Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value).  We value at lower of cost or market the slow moving and obsolete inventories based upon current and expected future product sales and the expected impact of product transitions or modifications.  Historically, the inventory write-offs have generally been within our expectations. Inventories consist of the following:

 September 30, 2015  March 31, 2015  June 30, 2016  December 31, 2015 
          
Raw materials $3,502,000  $3,156,000  $4,584,000  $2,385,000 
Work-in-process  38,000   527,000   8,000   793,000 
Finished goods  1,424,000   1,143,000   1,089,000   1,407,000 
                
 $4,964,000  $4,826,000  $5,681,000  $4,585,000 

Inventories acquired in a business combination are recorded at their estimated fair value less profit for sales efforts and expensed in cost of sales as that inventory is sold.  OnAs of March 31, 2015, inventories included anthe purchase accounting adjustment amount of $240,000 related to VSCI inventory was recorded at estimated fair value. During the six months ended September 30, 2015, the full amount has been recorded as an addition toin cost of goods sold.sold over approximately the first four months of the transition period ended December 31, 2015.

Page 15
Table of Contents
Note 8.Net Loss per Common Share

We calculate basic net loss per common share amounts by dividing net loss by the weighted-average common shares outstanding, excluding outstanding shares contingently subject to forfeiture.  For calculating diluted net loss per common share amounts, we add additional shares to the weighted-average common shares outstanding for the assumed exercise of stock options and vesting of restricted shares, if dilutive.  Because we had a net loss during the six months ended SeptemberJune 30, 20152016 and 20142015 the following options and warrants and outstanding and unvested restricted stock to purchase shares of our common stock were excluded from diluted net loss per common share because of their anti-dilutive effect, and therefore, basic net loss per common share equals dilutive net loss per common share:

  
Number of
options, warrants and
unvested restricted
stock
  
Range of stock
option and warrant
exercise prices
 
     
SeptemberJune 30, 20162,814,000$0.88 to $24.40
June 30, 2015  2,882,0003,767,000  $1.64 to $24.40 
September 30, 20141,506,739$  2.06 to $2.50

Note 9.Shareholders’ Equity

Share-based compensation.  On SeptemberJune 30, 2015,2016, the Company had one active plan, the Cogentix Medical 2015 Omnibus Incentive Plan, for share-based compensation grants (“the 2015 Plan”). Under the 2015 Plan, if we have a change in control, all outstanding grants, including those subject to vesting or other performance targets, fully vest immediately.  Under the 2015 Plan, we reserved 2,500,000 shares of our common stock for share-based grants and 1,403,734980,256 shares remain available for grant on SeptemberJune 30, 2015.2016.

We recognize share-based compensation expense in our Condensed Consolidated Statement of Operations based on the fair value at the time of grant of the share-based payment over the requisite service period.  We incurred approximately $640,000$225,000 and $661,000$559,000 in share-based compensation expense for the six months ended SeptemberJune 30, 20152016 and 2014,2015, respectively.

On SeptemberJune 30, 2015,2016, we had approximately $844,000$285,000 of unrecognized share-based compensation expense, net of estimated forfeitures, related to stock options that we expect to recognize over a weighted-average period of approximately 1.622.2 years.  We also had $1,415,000$528,000 of unrecognized share-based compensation expense, net of estimated forfeitures, related to restricted shares that we expect to recognize over a weighted-average period of approximately 1.82.23 years.

We grant option awards with an exercise price equal to the closing market price of our stock at the date of the grant.  Options granted under this plan generally expire over a period ranging from five to seven years from date of grant and vest at varying rates ranging up to three years.

Page 16
Table of Contents
We determined the fair value of our option awards using the Black-Scholes option pricing model.  We used the following weighted-average assumptions to value the options granted during the six months ended SeptemberJune 30:

 2015  2014  2016  2015 
          
Expected life in years  3.84   2.81   3.82   3.84 
Risk-free interest rate  1.1%  1.0%  0.94%  1.11%
Expected volatility  63.94%  66.41%  64.32%  63.94%
Expected dividend yield  0%  0%  0%  0%
Weighted-average grant date fair value $0.79  $1.21  $0.47  $0.79 

The expected life for options granted represents the period of time we expect options to be outstanding based on historical data of option holder exercise and termination behavior for similar grants.  The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate over the expected life at the time of grant.  Expected volatility is based upon historical volatility of our stock.  We estimate the forfeiture rate for stock awards to be approximately 10%15% for executive employees and directors and approximately 15%20% for non-executive employees for the six months ended September 30, 2015,calendar year 2016 awards based on our historical experience.

Page 16
Table of Contents
The following table summarizes the activity related to our stock options during the six months ended SeptemberJune 30, 2015:2016:

 
Number of
shares
  
Weighted
average
exercise price
  
Weighted
average
remaining
life in years
  
Aggregate
intrinsic
value
  
Number of
shares
  
Weighted
average
exercise price
  
Weighted
average
remaining
life in years
  
Aggregate
intrinsic
value
 
                    
Outstanding at March 31, 2015  2,251,085  $5.32   5.06  $0 
Outstanding at December 31, 2015  2,573,640  $4.46   5.24  $- 
Options granted  617,914   1.64           392,400   0.98         
Options exercised  -   -           -   -         
Options surrendered  (170,605)  5.46           (795,762)  3.20         
                                
Outstanding at September 30, 2015  2,698,394  $4.47   5.26  $0 
Outstanding at June 30, 2016  2,170,278  $4.30   4.93  $- 
                                
Exercisable at September 30, 2015  1,817,279  $5.51   3.91  $0 
Exercisable at June 30, 2016  1,569,490  $5.44   3.21  $- 

The total fair value of stock options that vested during the six months ended SeptemberJune 30, 2016 and 2015 was approximately $252,000 and 2014 was $503,000 and $620,000,$152,000, respectively.

Our 2015 Plan also permits the compensation committee of our board of directors to grant other stock-based benefits, including restricted shares. The following table summarizes the activity related to our restricted shares during the six months ended SeptemberJune 30, 2015:2016:

 Number of  Shares  
Weighted 
average
grant date
fair value
  
Weighted
average
remaining
life in years
  
Aggregate
intrinsic
value
  
Number of
Shares
  
Weighted
average
grant date
fair value
  
Weighted
average
remaining
life in years
  
Aggregate
intrinsic
value
 
                
Balance at March 31, 2015
  
317,741
  $4.47   
1.93
  $387,644 
Balance at December 31, 2015
  
686,910
  $2.41   
1.59
  $886,114 
Shares granted  513,299   1.62           337,858   0.98         
Shares vested  (121,445)  4.42           (311,503)  2.11         
Shares forfeited  (20,869)  2.66           (295,523)  2.50         
                                
Balance at September 30, 2015  688,726  $2.41   1.8  $854,020 
Balance at June 30, 2016  417,742  $1.41   2.23  $401,032 

The aggregate intrinsic value shown above for the restricted shares represents the total pre-tax value based on the closing price of our common stock at the end of each period.

Stock Warrants-Related Party.  On SeptemberJune 30, 2015,2016, the Company has warrants outstanding that were issued to Mr. Lewis C. Pell, a member of the Company’s board of directors, to purchase an aggregate of 376,123 shares of our common stock at a weighted average exercise price of $9.31 per share.  The duration in which the warrants may be exercised commences on the earlier of (i) March 31, 2018 or (ii) three days prior to the record date established for the declaration of any dividend or distribution of any rights in respect to our common stock in cash or other property other than our common stock, and terminates on the later of (x) the maturity date of the convertible promissory notes or (y) the date the convertible promissory notes are paid in full or converted into shares.  In addition, the warrants may be exercised immediately prior to a change in control.

Page 17
Long-Term Incentive Plan and Awards.  On October 1, 2014, the compensation committee of our board of directors and our board of directors approved and adopted a Performance Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan, as amended, and on October 2, 2014, grants of Performance Awards (the “Awards”) were made to members of our senior management team.

Performance goals for the Awards are based on the achievement of specified stock price targets during the period beginning on the date of grant and ending on the fourth anniversary of the date of grant or, if earlier, the closing date of a change of control (as defined in the Plan) of the Company (the “Performance Period”).  The stock price targets under the Awards are: $7.57 price per share of common stock, $10.32 price per share of common stock and $13.76 price per share of common stock.

A stock price target is considered achieved on the date (a) the average closing price of a share of our common stock equals or exceeds a stock price target for at least 45 consecutive trading days or (b) of the consummation of a change of control of the Company, provided the closing price of a share of our common stock on the last trading day immediately preceding the closing date of the change of control equals or exceeds a stock price target not previously achieved during the Performance Period.
Page 17

The Awards are accounted for as liability awards under the share-based compensation accounting guidance, as the awards are based on the performance of our common stock and are expected to be settled in cash.  Expense for the awards is recognized over the derived service period of approximately 2.4 years. We recorded a liability of $47,000approximately $28,000 at September 30, 2015June 31, 2016 and related reversal of expense was $(106,000)approximately $49,000 for the six months ended ending SeptemberJune 30, 20152016 for the Awards.

Note 10.Convertible Debt – Related Party

The following table is a summary of our convertible debt – related party on SeptemberJune 30, 2015:2016:

 
Gross
Principal
Amount
  
Unamortized
Debt
Discount
 
Net
Amount
  
Gross
Principal
Amount
  
Unamortized
Debt
Discount
  
Net
Amount
 
               
Note Payable A $20,000,000  $(3,831,750) $16,168,250  $20,000,000  $(3,248,007) $16,751,993 
                        
Note Payable B  3,500,000   (591,600)  2,908,400   3,500,000   (501,474)  2,998,526 
                        
Note Payable C  4,990,000   (1,002,080)  3,987,920   4,990,000   (849,419)  4,140,581 
 $28,490,000  $(5,425,430) $23,064,570  $28,490,000  $(4,598,900) $23,891,100 

The Convertible Debt-Related Party is held by Mr. Lewis C. Pell, a member of the Company’s board of directors, and consists of three convertible promissory notes.

•  Note Payable A accrues annual interest at the rate of 0.84%. The outstanding principal amount of Note Payable A is convertible into shares of our common stock at a conversion price of $6.00 per share.

•  Note Payable B accrues annual interest at the rate of 1.66%. The outstanding principal amount of Note Payable B is convertible into shares of our common stock at a conversion price of $4.45 per share.

•  Note Payable C accrues annual interest at the rate of 1.91%. The outstanding principal amount of Note Payable C is convertible into shares of our common stock at a conversion price of $5.55 per share.

At SeptemberJune 30, 2015,2016, we had an aggregate amount of $676,165$935,974 in accrued interest under the convertible notes payable, which is included in accrued expensesshown as interest payable on our consolidated balance sheet.

The convertible promissory notes mature on March 31, 2020 or earlier upon a change of control (as defined).  The convertible promissory notes generally cannot be converted by Mr. Pell prior to March 31, 2018. The convertible promissory notes may be converted earlier prior to a change in control or in connection with our prepayment of the convertible promissory notes.  The convertible promissory notes may be prepaid, at our option and upon 15 days’ notice to Mr. Pell, without other premium or penalty, with a combination of cash and common stock.  Interest on the convertible promissory notes is payable on the maturity date or upon repayment or conversion of all or any portion of the principal under the note.

Page 18
Under purchase accounting for the Merger, the convertible promissory notes were recorded at fair value on the effective date of the Merger, resulting in a discount from their face value of $5,960,000 as of March 31, 2015. The discount is being amortized over the remaining term based on the effective interest rate method with an imputed interest rate of 4.72%.

Note 11.Savings and Retirement Plans

We sponsor various retirement plans for eligible employees in the United States, the United Kingdom, and The Netherlands. Our retirement savings plan in the United States conforms to Section 401(k) of the Internal Revenue Code and participation is available to substantially all employees. We may also make discretionary contributions ratably to all eligible employees. We made discretionary contributions to the U.S. plan of $166,000$305,000 and $137,000$162,000 for the six months ended SeptemberJune 30, 2015,2016, and 2014,2015, respectively.
Page 18

Our international subsidiaries have defined benefit retirement plans for eligible employees.  These plans provide benefits based on the employee’s years of service and compensation during the years immediately preceding retirement, termination, disability, or death, as defined in the plans.

The cost for our defined benefit retirement plans in The Netherlands and the United Kingdom includes the following components for the three- and six-month periods ended SeptemberJune 30:

 
Three Months Ended
September 30
  
Six Months Ended
September 30
  
Three Months Ended
June 30
  
Six Months Ended
June 30
 
 2015  2014  2015  2014  2016  2015  2016  2015 
                    
Gross service cost $36,000  $36,000  $72,000  $71,000  $28,000  $36,000  $56,000  $65,000 
Interest cost  24,000   35,000   48,000   73,000   29,000   24,000   58,000   53,000 
Expected return on assets  (19,000)  (27,000)  (38,000)  (54,000)  (24,000)  (19,000)  (49,000)  (39,000)
Amortization  7,000   1,000   14,000   2,000   (1,000)  7,000   (3,000)  7,000 
Net periodic retirement cost $48,000  $45,000  $96,000  $92,000  $32,000  $48,000  $62,000  $86,000 

Note 12.Business Segment Information

ASC 280, “Segment Reporting,” establishes disclosure standards for segments of a company based on management’s approach to defining operating segments.  Reportable segments are defined primarily by the nature of products and services, the nature of the production processes, and the type of customers for our products and services.

We operate in two markets, the medical market and the industrial market.  Within the medical market, we have a number of product lines, endoscopy-based products, including our PrimeSight flexible fiber and video endoscopes used in the practices of urology, pulmonology, trans-nasal esophagoscopy and ENT (ear, nose and throat) and a proprietary sterile disposable microbial barrier, known as EndoSheath technology,Protective Barrier, the Urgent PC®® PC Neuromodulation System (“Urgent PC System”) a minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder and associated symptoms; and Macroplastique® Implants (“Macroplastique”), an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence.

None of the industrial market sales, net losses or assets are more than 10% of our total sales, losses or assets.  Therefore, we aggregate our operating segments into one reportable segment in accordance with the objectives and principles of the applicable guidance.

Page 19
For the three and six months ended SeptemberJune 30, 2015,2016, no country other than the United States represented more than 10% of our consolidated revenue.  Information regarding net sales to customers by geographic area for the three and six months ended SeptemberJune 30 is as follows:

  
United
States
  
United
Kingdom
  
All Other
Foreign
Countries (1)
  Consolidated 
         
Three months ended September 30, 2015 $8,828,000  $596,000  $2,410,000  $11,834,000 
                 
Three months ended September 30, 2014 $4,896,000  $627,000  $932,000  $6,455,000 
                 
Six months ended September 30, 2015 $17,142,000  $1,227,000  $4,616,000  $22,985,000 
                 
Six months ended September 30, 2014 $9,429,000  $1,287,000  $2,123,000  $12,839,000 
  
United
States
  
United
Kingdom
  
All Other
Foreign
Countries (1)
  Consolidated 
             
Three months ended June 30, 2016 $9,533,000  $1,196,000  $2,276,000  $13,005,000 
                 
Three months ended June 30, 2015 $7,274,000  $1,077,000  $2,799,000  $11,150,000 
                 
Six months ended June 30, 2016 $18,176,000  $2,184,000  $4,851,000  $25,211,000 
                 
Six months ended June 30, 2015 $12,732,000  $1,660,000  $3,778,000  $18,170,000 

(1)No other country accounts for 10% or more of the consolidated net sales.
Information regarding geographic area in which we maintain long-lived assets is as follows:

  
United
States
  
All Other
Foreign
Countries (1)
  Consolidated 
       
September 30, 2015 $2,115,000  $491,000  $2,606,000 
             
March 31, 2015 $1,397,000  $475,000  $1,872,000 

(1)Substantially all maintained in The Netherlands
  
United
States
  
United
Kingdom
  
The
Netherlands
  Consolidated 
             
June 30, 2016 $1,841,000  $2,000  $462,000  $2,305,000 
                 
December 31, 2015 $2,089,000  $3,000  $463,000  $2,555,000 

Accounting policies of the operations in the various geographic areas are the same as those described in Note 1.  Net sales attributed to each geographic area are net of intercompany sales.  No single customer represents 10% or more of our consolidated net sales.  Long-lived assets consist of property, plant and equipment.

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-looking Statements

We recommend that you read this quarterly report on Form 10-Q in conjunction with our annual report on Form 10-K10-KT for the fiscal yearnine-months ended MarchDecember 31, 2015.

You should read the following discussion of our financial condition and results of operation together with the unaudited consolidated financial statements and the notes thereto included elsewhere in this report and other financial information included in this report.  The following discussions may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, as we discussed in our special note regarding “Forward-Looking Statements” beginning on page 3 of this report and under “Part I - Item 1A. Risk Factors” in our annual report on Form 10-K10-KT for the fiscal yearnine-months ended MarchDecember 31, 2015.  These risks could cause our actual results to differ materially from any further performance suggested below.

We do not undertake, nor assume any obligation, to update any forward-looking statement that we may make from time to time.

Overview

Cogentix Medical Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company.  We design, develop, manufacture and market innovative proprietary technologies serving the urology urogynecology/gyn, ENT (ear, nose and throat) and gastrointestinalairway management markets.  The Urgent®Urgent® PC Neuromodulation System is an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) which has FDA clearance for the office-based treatment of overactive bladder (OAB) and has regulatory approvals for the treatment of OAB and fecal incontinence (FI) in various international markets..  The FDA-cleared and CE marked EndoSheath®PrimeSightTM Endoscopy Systems utilizing the EndoSheath Protective Barrier combine state-of-the-art endoscopic technology with a sterile, disposable microbial barrier, providing practitioners and healthcare facilities with a solution to meet the growing need for safe, efficient and cost-effective flexible endoscopy.  The CompanyWe also offers Macroplastique®,offer Macroplastique® a urethral bulking agent for the treatment of stress urinary incontinence.  Outside the U.S., the Companycompany markets additional bulking agents: PTQ®PTQ® for the treatment of fecal incontinence and VOX®the VOX® for vocal cord augmentationaugmentation.
On December 21, 2014, Vision-Sciences entered into a merger agreement with Uroplasty, a publicly traded corporation.  The merger agreement provided for the merger of Uroplasty with and vesicourethral reflux.

The Company isinto a newly created, wholly-owned merger subsidiary of Vision-Sciences.  Following the resultapproval of the merger by Vision-Sciences’ and Uroplasty’s stockholders on March 30, 2015 and pursuant to the terms of the merger agreement, on March 31, 2015, mergerUroplasty merged with and into the  Merger Sub, with Merger Sub continuing as the surviving entity and a wholly-owned subsidiary of two medical device companies, Uroplasty,Vision-Sciences under the name “Uroplasty, LLC.”  Vision-Sciences changed its name to “Cogentix Medical, Inc. and Vision-Sciences, Inc. ”
The Mergermerger was accounted for as a reverse acquisition due to a number of factors including the relative voting interests in the combined company of the former Vision-Sciences and Uroplasty stockholders following the Merger.merger.  As a result, Uroplasty and its consolidated subsidiaries represent the accounting acquirer in the merger, and Vision and its consolidated subsidiary represent the legal acquirer in the Merger.merger.  Accordingly, while Vision was the legal acquirer in the merger, Uroplasty is treated as the acquiring company in the Mergermerger for accounting purposes.

As a result of the Merger,merger, our financial statements prior to March 31, 2015 are the historical financial statements of Uroplasty, and our financial statements on and after March 31, 2015 reflect the results of the operations of Uroplasty and Vision-Sciences on a combined basis.  We refer you to Note 2 to the “Notes to Consolidated Financial Statements” in Part II, Item 8 of this report for additional description of this merger, the accounting treatment of the merger, and the pro forma financial information for Cogentix on a combined basis.

Critical Accounting Policies

We prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, which require us to make estimates and assumptions in certain circumstances that affect amounts reported.  In preparing these consolidated financial statements, we have made our best estimates and judgments of certain amounts, giving due consideration to materiality.
We have identified in our annual report on Form 10-K10-KT for the fiscal yearnine-months ended MarchDecember 31, 2015, our “critical accounting policies,” which are certain accounting policies that we consider important to the portrayal of our results of operations and financial condition and which may require the application of a higher level of judgment by our management, and as a result are subject to an inherent level of uncertainty.  Management made no significant changes to our critical accounting policies during the six months ended SeptemberJune 30, 2015.2016.

Results of Operations

Three and six months ended September 30, 2015 compared to three and six months ended September 30, 2014

The reported operations for the three months ended June 30, 2016 and 2015 and the six months ended SeptemberJune 30, 20152016, are the results of Cogentix, while the reported operations for the three and six months ended SeptemberJune 30, 2014 only2015 include the results of Uroplasty.   Therefore, starting inUPI for the first quarterperiod from January 1, 2015 through March 31, 2015 and the results of fiscal 2016, our reported numbers have been andCogentix Medical, Inc. beginning April 1, 2015, the day after the merger was closed.  As such, results for the six month current period will be materially different than the reported numbers of the same period of the prior years.year.

Three months ended June 30, 2016 compared to three months ended June 30, 2015

Net Sales:  During the three months ended September 30, 2015,current period, consolidated net sales of $11,834,000$13,005,000 represented a $5,379,000,$1,855,000, or an 83%a 17% increase, over net sales of $6,455,000$11,150,000 for the three months ended September 30, 2014. The increase in consolidated net sales for the three months ended September 30, 2015 was due to the Merger.prior period.  The revenue for the products from Vision-Sciences totaled $4,588,000increased $1,071,000, or 25%, in the three months ended September 30, 2015.  The remainder of thecurrent period.  This increase is primarily due to theour sales force becoming more proficient in selling this technology as well as an increase in revenueorders for our industrial business.  Revenue from Urgent PC.

During® PC increased $722,000, or 15%.  While a new competitor to Urgent PC entered the six months ended September 30, 2015, consolidated netmarket in early 2016, our sales team has effectively demonstrated the clinical efficacy and value proposition of $22,984,000 represented a $10,145,000, or a 79% increase, over net sales of $12,839,000 for the six months ended September 30, 2014. The increase in consolidated net sales for the six months ended September 30, 2015 was dueUrgent PC to the Merger.  The revenue for the products from Vision-Sciences totaled $8,830,000our physician customers resulting in the six months ended September 30, 2015.increased sales. The remainder of the increase is primarily duesales team continues to the increase in revenue from Urgent PC.place a strong emphasis on servicing existing accounts and increasing utilization within existing accounts.

Net sales to customers in the U.S. of $8,828,000$9,614,000 during the three months ended September 30, 2015,current period represented an increase of $3,931,000,$1,300,000, or 80%16%, over net sales of $4,897,000$8,314,000 in the prior period. Net sales to customers outside the U.S. increased $554,000 (20%) to $3,391,000 in the current period, compared to $2,837,000 in the prior period.

Gross Profit:  Gross profit was $8,917,000, or 68.6% of net sales in the current period, compared to $7,498,000, or 67.2% of net sales in the prior period.  The increase in gross profit percentage is attributed primarily to an unprofitable Stryker Corporation distribution arrangement for ureteroscopes that was not renewed at the end of calendar 2015.

General and Administrative Expenses (G&A):  G&A expenses of $1,867,000 in the current period decreased $26,000 from $1,893,000 in the prior period.

Research and Development Expenses (R&D):  R&D expenses of $1,100,000 in the current period increased $38,000 from $1,062,000 in the prior period.
Selling and Marketing Expenses (S&M):  S&M expenses of $5,433,000 in the current period, decreased $1,218,000, from $6,651,000 in the prior period.  The decrease is attributed primarily to a decrease in sales personnel and travel costs due to lower headcount as a result of the Merger, lower consulting costs, the timing of our national sales meeting, and the repeal of the medical device tax.

Amortization of Intangibles: Amortization of intangibles was $591,000 in the current period compared to $634,000 in the prior period.  The decrease is due to some identifiable intangible assets recorded as part of the Merger that are now fully amortized.

Proxy Settlement Costs: On May 23, 2016, the Company and all of the then-current members of the Board of Directors of the Company, including Director Mr. Lewis Pell who had been independently soliciting proxies to support his proposals for the Company’s 2016 Annual Meeting of Stockholders originally scheduled for May 20, 2016 and adjourned for May 24, 2016, entered into an agreement to settle the pending proxy contest between the Company and Mr. Pell and related litigation in connection with the Annual Meeting (the “Settlement”).  For the three months ended SeptemberJune 30, 2014. This increase is due2016, the Company incurred $2,178,000 of costs related to $3,020,000the Settlement, including $678,000 of revenueprofessional fees (primarily legal) and $1,500,000 of severance costs for the Company’s former CEO.  There were no similar costs in the same period of the prior year.

Merger Related Costs:  Merger related costs totaled $469,000 in the three months ended SeptemberJune 30, 2015.  There were no similar costs in the current period.  Merger related costs include severance and retention, consulting and professional fees.

Other Income (Expense):  Other income (expense) includes interest income, interest expense, foreign currency exchange and other non-operating costs when incurred.  Net other expense was $394,000 in the current period compared to net other expense of $339,000 in the prior period.  Interest expense total $376,000 in the current period compared to $343,000 in the prior period.  This interest expense is primarily due to accrued interest on related party debt and the amortization of the debt discount associated with this debt as a result of the merger with Vision-Sciences.

The related party debt has a weighted average stated interest rate of 1.13% resulting in $83,000 of interest expense for the current period, compared to $76,000 in the prior period.   For the current period, the non-cash amortization of the debt discount totaled $279,000, compared to $266,000 in the prior period.

Income Tax Expense:  We recorded income tax expense of approximately $19,000 in the current period and $18,000 in the prior period.  Income tax expense is attributed to our European subsidiaries and to the payment of minimum taxes in the U.S.

Six months ended June 30, 2016 compared to six months ended June 30, 2015

Net Sales:  During the current period, consolidated net sales of $25,211,000 represented a $7,041,000 or a 39% increase over net sales of $18,170,000 in the prior period.  The revenue for the products from Vision-Sciences increased $6,030,000, or 40% in the Vision-Sciences products and $829,000current period.  The primary reason for this increase in domesticis the Merger, which occurred on March 31, 2015.  Revenue from Urgent® PC increased $1,035,000, or 11%.  While a new competitor to Urgent PC revenue.entered the market in early 2016, our sales team has effectively demonstrated the clinical efficacy and value proposition of Urgent PC to our physician customers resulting in the increased sales. The sales team continues to place a strong emphasis on servicing existing accounts and increasing utilization within existing accounts.

Net sales to customers in the U.S. of $17,142,000$18,532,000 during the six months ended September 30, 2015,current period represented an increase of $7,713,000,$4,662,000, or 82%34%, over net sales of $9,429,000 for the six months ended September 30, 2014. This increase is due to $5,922,000 of revenue$13,870,000 in the six months ended September 30, 2015 from the Vision-Sciences products and $1,625,000 increase in domestic Urgent PC revenue.

prior period. Net sales to customers outside the U.S. for the three months ended September 30, 2015 increased $1,448,000 or 93%$2,379,000 to $3,006,000,$6,679,000, compared to $1,558,000 for the three months ended September 30, 2014. This increase is due to $1,568,000 of revenue in the three months ended September 30, 2015 from the Vision-Sciences

Net sales to customers outside the U.S. for the six months ended September 30, 2015 increased $2,432,000 or 71% to $5,842,000, compared to $3,410,000 for the six months ended September 30, 2014. This increase is due to $2,907,000 of revenue in the six months ended September 30, 2015 from the Vision-Sciences products offset by a decrease in Urgent PC and Macroplastique.  Substantially all of the international Urgent PC and Macroplastique revenue decline is due to changes in foreign currency exchange rates.

Global revenue from Urgent PC totaled $5,067,000, representing an $815,000 increase, or 19%, over net sales of $4,252,000 for the three months ended September 30, 2014.  Global revenue from Urgent PC totaled $9,752,000, representing a $1,440,000 increase, or 17%, over net sales of $8,312,000 for the six months ended September 30, 2014.  The increase for both periods is a result of improved sales execution within the U.S, an increase in the number of active customers and higher utilization per customer.

Global revenue from our Endosheath technology platform (inclusive of endoscopes, sheaths, service and peripherals) totaled $4,588,000 in the three months ended September 30, 2015.  Global revenue from these products totaled $8,829,000 in the six months ended September 30, 2015.  All revenue from products based on the Endosheath technology platform for both the three month and six month periods ended September 30, 2015 is incremental over the same period$4,300,000 in the prior year as the Merger occurred on March 31, 2015.period.

Global Macroplastique revenue totaled $1,882,000, a decrease of $42,000 or 2% for the three months ended September 30, 2015 over the same period in the prior year.  Global Macroplastique revenue totaled $3,822,000 for the six months ended September 30, 2015, a decrease of $181,000 or 5% over the same period in the prior year.  Excluding the impact of fluctuations in foreign currency exchange rates, global revenue for Macroplastique would have been flat for the three months ended September 30, 2015 and $3,937,000, a decrease of 3% for the six months ended September 30, 2015.  Macroplastique serves a small market relative to our Urgent PC and Endosheath product lines and is not a primary focus of our sales team.
Gross Profit:  Gross profit was $7,880,000,$17,323,000, or 66.6%68.7% of net sales duringin the three months ended September 30, 2015,current period, and $5,701,000,$13,716,000, or 88.3%75.5% of net sales forin the three months ended September 30, 2014.prior period.  The decrease in gross profit percentage for the three-month period ended September 30, 2015 is attributed primarily to the addition of the Vision-Sciences products which have lower margins than the Uroplasty products.

Gross profit was $15,378,000, or 66.9% of net sales during the six months ended September 30, 2015, and $11,295,000, or 88.0% of net sales for the six months ended September 30, 2014.  The decrease in gross profit percentage for the six-month period ended September 30, 2015 is attributed primarily to the addition of the Vision-Sciences products which have lower margins than the Uroplasty products.

General and Administrative Expenses (G&A):  G&A expenses of $1,935,000 during$3,530,000 in the three months ended September 30, 2015,current period increased $647,000$234,000 from $1,288,000 during$3,296,000 in the sameprior period in 2014. G&A expenses of $3,829,000 during the six months ended September 30, 2015, increased $963,000 from $2,866,000 during the same period in 2014. Both the three and six-month periods ended September 30, 2015 included the G&A expenses of Vision-Sciences, offset by cost synergies relateddue to the merger including lower headcount, lower legal and accounting and lower public company costs.Merger.

Research and Development Expenses (R&D):  R&D expenses of $1,035,000 during$2,037,000 in the three months ended September 30, 2015current period increased $384,000$365,000 from $651,000 during$1,672,000 in the same period in 2014.  R&D expenses of $2,109,000 during the six months ended September 30, 2015 increased $549,000 from $1,560,000 during the same period in 2014.prior period.  The increase for both periods is attributed primarily to the Merger, offset partially by lower personnel costs and lower expenditure on R&D projects.

Selling and Marketing Expenses (S&M):  S&M expenses of $5,846,000 during$11,069,000 in the three months ended September 30, 2015, increased $1,027,000,current period, decreased $527,000, from $4,819,000, during$11,596,000 in the sameprior period in 2014.  S&M expenses of $12,497,000 during the six months ended September 30, 2015, increased $2,406,000, from $10,091,000, during the same period in 2014..  The increasedecrease is attributed primarily to an increasea decrease in sales personnel costs from the Merger, offset by cost synergies relateddue to the Merger including lower headcount and lowerreduced marketing project spend.

Amortization of Intangibles: Amortization of intangibles was $634,000 and $8,000 for$1,182,000 in the three months ended September 30, 2015 and 2014, respectively.  Amortization of intangibles was $1,268,000 and $17,000 forcurrent period compared to $641,000 in the six months ended September 30, 2015 and 2014, respectively.prior period.  The increase is due to the establishment of $13,660,000 of identifiable intangible assets on March 31, 2015, as a part of the allocation of purchase accounting.  These identifiable intangible assets are being amortized over a weighted average life of approximately 6 years.

Proxy Settlement Costs: On May 23, 2016, the Company and all of the then-current members of the Board of Directors of the Company, including Director Mr. Lewis Pell who had been independently soliciting proxies to support his proposals for the Company’s 2016 Annual Meeting of Stockholders originally scheduled for May 20, 2016 and adjourned for May 24, 2016, entered into an agreement to settle the pending proxy contest between the Company and Mr. Pell and related litigation in connection with the Annual Meeting (the “Settlement”).  For the six months ended June 30, 2016, the Company incurred $2,312,000 of costs related to the Settlement, including $812,000 of professional fees (primarily legal) and $1,500,000 of severance costs for the Company’s former CEO.  There were no similar costs in the same period of the prior year.

Merger Related Costs:  Merger related costs totaled $437,000 and $906,000 for$2,047,000 in the three and six month periodsmonths ended SeptemberJune 30, 2015, respectively.2015.  There were no similar costs in the prior year periods.current period.  Merger related costs include severance and retention, consulting and professional fees related to the Merger.fees.

Other Income (Expense):  Other income (expense) includes interest income, interest expense, was $351,000 for the three months ended September 30, 2015, compared to nil in the three months ended September 30, 2014.  Other expense was $690,000 for the six months ended September 30, 2015, compared toforeign currency exchange and other income of $4,000 in the six months ended September 30, 2014.  The increase innon-operating costs when incurred.  Net other expense was due$792,000 in the current period compared to interest recognized onnet other expense of $338,000 in the prior period.  Other expense increased primarily as the result of the acquisition of related party debt assumed inand the Merger.amortization of the debt discount along with accrued interest associated with this debt as a result of the merger with Vision-Sciences.

The related party debt has a weighted average stated interest rate of the 1.07%1.13% resulting in $76,000 and $152,000$178,000 of interest expense for the three and six months ended September 30, 2015, respectively.current period.  Further, as part of the purchase price accounting related to the Merger, the related partparty debt was discounted to fair value.  For the three months ended September 30, 2015,current period, the non-cash amortization of the debt discount totaled $266,000 and for the six months ended September 30, 2015, the non-cash amortization of the debt discount totaled $535,000.$554,000.

Income Tax Expense:  During the three months ended September 30, 2015 and 2014, weWe recorded income tax expense of approximately $11,000$33,000 in the current period and $15,000, respectively. During$27,000 in the six months ended September 30, 2015 and 2014, we recorded income tax expense of approximately $28,000 and $35,000, respectively.prior period.  Income tax expense is attributed to our European subsidiaries and to the payment of minimum taxes in the U.S.

Non-GAAP Financial Measures:  The following table reconciles our operating income/loss calculated in accordance with GAAP to non-GAAP financial measures that exclude non-cash charges for share-based compensation expense, long-term incentive plan, and depreciation and amortization, as well as Merger-related costs.proxy settlement costs incurred in 2016 and merger-related costs in 2015.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.
We use thesethis non-GAAP financial measures,information, and in particular non-GAAP cash operating income/loss, for internal managerial purposes because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measuresthis information to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.  For the tables below, the three and six month periods ended September 30, 2014 are on a Pro forma combined basis.

Our non-GAAP cash operating loss, excluding non-cash expenses, proxy settlement and merger related costs, during the three months ended SeptemberJune 30, 2016 and 2015 was $827,000 and 2014 was approximately $(383,000) and $(1,714,000)$(1,691,000), respectively. Our non-GAAP cash operating loss, excluding non-cash expenses and merger related costs during the six months ended SeptemberJune 30, 2016 and 2015 was $1,274,000 and 2014 was approximately $(2,074,000) and $(5,025,000)$(2,036,000), respectivelyrespectively..

  Expense Adjustments   
Three-Months Ended GAAP  
Share-
based
Expense
  
Long-term
Incentive
Plan
  Depreciation  Amortization  Non-GAAP 
September 30, 2015            
Gross profit $7,880,000  $8,000  $-  $59,000  $-  $7,947,000 
% of net sales  66.6%                  67.2%
Operating expenses                        
General and administrative  2,299,000   (313,000)  77,000   (54,000)  -   2,009,000 
Research and development  1,035,000   (19,000)  -   (1,000)  -   1,015,000 
Selling and marketing  5,920,000   (73,000)  -   (104,000)  -   5,743,000 
Amortization  634,000   -   -   -   (634,000)  - 
   9,888,000   (405,000)  77,000   (159,000)  (634,000)  8,767,000 
                         
Operating loss $(2,008,000) $413,000  $(77,000) $218,000  $634,000  $(820,000)
Merger Related  costs  437,000                   437,000 
Operating loss excluding merger related costs $(1,571,000)                 $(383,000)
                         
September 30, 2014                        
Gross profit $5,701,000  $11,000  $-  $4,000  $-  $5,716,000 
% of net sales  88.3%                  88.6%
Operating expenses                        
General and administrative  1,288,000   (231,000)  -   (36,000)  -   1,021,000 
Research and development  651,000   (11,000)  -   (1,000)  -   639,000 
Selling and marketing  4,819,000   (84,000)  -   (18,000)  -   4,717,000 
Amortization  8,000   -   -   -   (8,000)  - 
   6,766,000   (326,000)  -   (55,000)  (8,000)  6,377,000 
                         
Operating loss - UPI $(1,065,000) $337,000  $-  $59,000  $8,000  $(661,000)
Operating loss – VSCI (non GAAP) $(1,441,000) $195,000  $-  $153,000  $40,000  $(1,053,000)
Consolidated operating loss – CGNT (non GAAP) $ (2,506,000) $532,000  $-  $212,000  $48,000  $(1,714,000)
 
  Expense Adjustments      Expense Adjustments    
Six-Months Ended GAAP  
Share-
based
Expense
  
Long-term
Incentive
Plan
  Depreciation  Amortization  Non-GAAP 
September 30, 2015            
Three-Months Ended GAAP  
Share-
based
Expense
  
Long-term
Incentive
Plan
  Depreciation  Amortization  Non-GAAP 
June 30, 2016                  
Gross profit $15,378,000  $18,000  $-  $111,000  $-  $15,507,000  $8,917,000  $18,000  $-  $43,000  $-  $8,978,000 
% of net sales  66.9%                  67.5%  68.6%                  69.0%
Operating expenses                                                
General and administrative  4,457,000   (440,000)  106,000   (112,000)  -   4,011,000   1,867,000   (113,000)  25,000   (52,000)  -   1,727,000 
Research and development  2,109,000   (36,000)  -   (9,000)  -   2,064,000   1,100,000   (15,000)  -   (1,000)  -   1,084,000 
Selling and marketing  12,763,000   (146,000)  -   (205,000)  -   12,412,000   5,433,000   5,000   -   (98,000)  -   5,340,000 
Amortization  1,268,000   -   -   -   (1,268,000)  -   591,000   -   -   -   (591,000)  - 
Proxy settlement costs  2,178,000   -   -   -   -   2,178,000 
  20,597,000   (622,000)  106,000   (326,000)  (1,268,000)  18,487,000  $11,169,000  $(123,000) $25,000  $(151,000) $(591,000) $10,329,000 
                                                
Operating loss $(5,219,000) $640,000  $(106,000) $437,000  $1,268,000  $(2,980,000) $ (2,252,000) $141,000  $(25,000) $194,000  $591,000  $(1,351,000)
Merger Related costs  906,000                   906,000 
Operating loss excluding merger related costs $(4,313,000)                 $(2,074,000)
Proxy settlement costs $2,178,000  -   -   -   -  $2,178,000 
Cash operating loss excluding proxy settlement costs                     $827,000 
                                                
September 30, 2014                        
June 30, 2015                        
Gross profit $11,295,000  $25,000  $-  $10,000  $-  $11,330,000  $7,498,000  $10,000  $-  $52,000  $-  $7,560,000 
% of net sales  88.0%                  88.2%  67.2%                  67.8%
Operating expenses                                                
General and administrative  2,866,000   (442,000)  -   (74,000)  -   2,350,000   1,893,000   (124,000)  29,000   (58,000)  -   1,740,000 
Research and development  1,560,000   (30,000)  -   (1,000)  -   1,529,000   1,062,000   (17,000)  -   (8,000)  -   1,037,000 
Selling and marketing  10,091,000   (164,000)  -   (37,000)  -   9,890,000   6,652,000   (74,000)  -   (104,000)  -   6,474,000 
Amortization  17,000   -   -   -   (17,000)  -   634,000   -   -   -   (634,000)  - 
Merger related costs  469,000   -   -   -   -   469,000 
  14,534,000   (636,000)  -   (112,000)  (17,000)  13,769,000  $10,710,000  $(215,000) $29,000  $(170,000) $(634,000) $9,720,000 
                                                
Operating loss - UPI $(3,239,000) $661,000  $-  $122,000  $17,000  $(2,439,000)
Operating loss – VSCI (non GAAP) $(3,321,000) $351,000  $-  $318,000  $66,000  $(2,586,000)
Consolidated operating loss – CGNT (non GAAP) $(6,560,000) $1,012,000  $-  $440,000  $83,000  $(5,025,000)
Operating loss $(3,212,000) $225,000  $(29,000) $222,000  $634,000  $(2,160,000)
Merger related costs $469,000   -   -   -   -  $469,000 
Cash operating loss excluding merger related costs                     $(1,691,000)
   Expense Adjustments    
Six-Months Ended GAAP  
Share-
based
Expense
  
Long-term
Incentive
Plan
  Depreciation  Amortization  Non-GAAP 
June 30, 2016                  
Gross profit $17,323,000  $22,000  $-  $93,000  $-  $17,438,000 
% of net sales  68.7%                  69.2%
Operating expenses                        
General and administrative  3,530,000   (140,000)  47,000   (106,000)  -   3,331,000 
Research and development  2,037,000   (9,000)  -   (1,000)  -   2,027,000 
Selling and marketing  11,069,000   (54,000)  - �� (209,000)  -   10,806,000 
Amortization  1,182,000   -   -   -   (1,182,000)  - 
Proxy settlement costs  2,312,000   -   -   -   -   2,312,000 
  $20,130,000  $(203,000) $47,000  $(316,000) $(1,182,000) $18,476,000 
                         
Operating loss $(495,000) $225,000  $(47,000) $409,000  $1,182,000  $(1,038,000)
Proxy settlement costs $2,312,000   -   -   -   -  $2,312,000 
Cash operating loss excluding proxy settlement costs                     $1,274,000 
                         
June 30, 2015                        
Gross profit $13,716,000  $21,000  $-  $56,000  $-  $13,793,000 
% of net sales  75.5%                  75.9%
Operating expenses                        
General and administrative  3,296,000   (346,000)  8,000   (100,000)  -   2,858,000 
Research and development  1,672,000   (28,000)  -   (8,000)  -   1,636,000 
Selling and marketing  11,596,000   (141,000)  -   (120,000)  -   11,335,000 
Amortization  641,000   -   -   -   (641,000)  - 
Merger related costs  2,047,000   -   -   -   -   2,047,000 
  $19,252,000  $(515,000) $8,000  $(228,000) $(641,000) $17,876,000 
                         
Operating loss $(5,536,000) $536,000  $(8,000) $284,000  $641,000  $(4,083,000 
Merger related costs $2,047,000   -   -   -   -  $2,047,000 
Cash operating loss excluding merger related costs                     $(2,036,000)

Liquidity and Capital Resources

Cash Flows.

On SeptemberJune 30, 2015,2016, our cash and cash equivalents balances totaled $2,929,0002,867,000 and we had working capital (current assets less current liabilities) of approximately $8,142,0007,838,000.

For the six months ended SeptemberJune 30, 2015, we2016, cash provided by operating activities was $1,062,000, compared to cash used$5,141,000 of cash in operating activities compared to $2,476,000 of cash used$4,063,000 during the six months ended SeptemberJune 30, 2014.  We2015.  For the six months ended June 30, 2016, we incurred a net loss of $3,631,000.  Proxy settlement costs of approximately $2,000,000 have been expensed but not yet paid as of June 30, 2016.  The severance of $1,500,000 included in the proxy settlement costs are to be paid over 18 months and certain legal fees have not yet been paid pending determination if any are reimbursable under our directors and officers insurance policy.  Further, non-cash depreciation and amortization expense totaled $1,591,000 and non-cash debt discount amortization totaled $554,000.  In addition, accounts receivables decreased by $1,691,000 due to strong collection efforts.    For the six months ended June 30, 2015, we used this cash primarily to fund the operating loss, net of non-cash charges for depreciation, amortization of intangibles, long-term incentive plan and share-based compensation of $2,980,0001,453,000 and paid approximately $2,220,000$2,047,000 of Mergermerger related expenses that were accrued for as of March 31, 2015, costs.during the six months ended September 30, 2015, and $2,439,000 during the six months ended September 30, 2014.
During the six months ended SeptemberJune 30, 2015,2016 we used $1,217,000 of net cash from investing activities primarily toof $167,000 for the purchase of property, plant and equipment, primarily due to the build out of our new leased facility in Massachusetts.equipment.  During the six months ended SeptemberJune 30, 2014,2015, we generated $3,324,000$1,411,000 of net cash from investing activities, primarily from cash acquired from the maturitymerger with Vision-Sciences, partially offset by purchases of marketable securities.property, plant and equipment.

Sources of Liquidity.

We have incurred substantial operating losses since our inception. We anticipate that for the full year fiscal 2016 we will incur negative cash flows from operations, driven by continued investment in a direct sales force for the U.S. market, spending for marketing and for research and development, integration of UPI and VSCI, and general business operations. However, we expect to be cash flow breakeven from operations in the second half of fiscal 2016.  As of September 30, 2015, we had cash and cash equivalents totaling approximately $2.9 million as well as a $7.0 millionobtained an 18-month line of credit (subject to eligible receivables and inventory) under which there were no borrowings.

through Venture Bank in September 2015.  We may obtain additional debt and/or equity financing during fiscalcalendar year 2016.  There can be no assurance that any additional financing will be available on terms acceptableWe have historically not generated cash from operations because we have yet to us, if at all. If required,achieve profitability, and to achieve profitability, we believemust generate substantially more revenue than we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.have generated this year or in prior years.

Our ability to achieve significant revenue growth will depend, in large part, on our ability to achieve widespread market acceptance of our products and successfully expand our business in the U.S.business.  We cannot guarantee that we will successfully achieve such revenue growth.  If we fail to meet our projections of profitability and cash flow, or determine to use cash for matters we are not currently projecting, we may need to seek additional financing to meet our cash needs.  We cannot assure you that such financing, if needed, will be available to us on acceptable terms, if at all.

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and are not required to provide the information required by this Item.

ITEM 4.CONTROLS AND PROCEDURES

Disclosure Controls and Procedures.

Under the supervision and with the participation of our management, including our President and Chief Executive Officer and Chief Financial Officer (“CEO and CFO”), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  Based on this evaluation, our CEO and CFO of our company concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms and that such information is accumulated and communicated to our management, including our CEO and CFO, in a manner that allows timely decisions regarding required disclosure.

Changes In Internal Controls Over Financial Reporting.

As part of our ongoing activities after the Merger, we are continuing to integrate our financial reporting functions and our controls and procedures.  We have also been augmenting our company-wide controls to reflect the risks inherent in a business combination of the magnitude and complexity of the Merger.  There have been no changes in internal controls since June 30,December 31, 2015.

PART II.OTHER INFORMATION
ITEM 1.
LEGAL PROCEEDINGS

Although we are not currently involved in any material legal proceedings, from timeOn May 23, 2016, Cogentix Medical, Inc. and all of its then-current members of the Board of Directors, including Mr. Lewis Pell who has been independently soliciting proxies to time we may be subjectsupport his proposals  for the Company’s 2016 Annual Meeting of Stockholders originally scheduled for May 20, 2016 and adjourned for May 24, 2016 (the “Annual Meeting”), entered into an agreement to varioussettle the pending or threatened legal actionsproxy contest between the Company and proceedings, including those that ariseMr. Pell and related litigation in the ordinary courseCourt of our business.  SuchChancery of the State of Delaware in connection with the Annual Meeting (the “Settlement Agreement”).

Under the terms of the Settlement Agreement, (i) the parties to the Settlement Agreement agreed to take all necessary steps, among other things, to qualify Messrs. Lewis Pell, Howard Zauberman and Dr. James D’Orta as Class I directors to be elected to serve on the Board, (ii) Mr. Robert Kill, the then-current President, Chief Executive Officer and Corporate Secretary of the Company, agreed to resign as an employee and officer of the Company and any of its affiliates and subsidiaries, including his position as the President, Chief Executive Officer and Corporate Secretary of the Company effective as of May 23, 2016 and Mr. Kill will receive severance payments in respect of any and all contracts with the Company and any of its affiliates and subsidiaries pursuant to the terms of a Separation and Release Agreement by and between the Company and Mr. Kill dated May 23, 2016 (the “Separation and Release Agreement”), (iii) Mr. Darin Hammers, the current Chief Operating Officer of the Company, was appointed to serve as the interim Chief Executive Officer and President for 90 days, after which time, on the condition of his adequate performance in the sole judgment of a majority of the Board, the Company intends to appoint him as Chief Executive Officer and President of the Company and a director on the Board to fill the vacancy created by Mr. Kill’s resignation, (iv) each of Messrs. Robert Kill, Kevin Roche, who had been serving as the Chair of the Governance and Nominating Committee, and Kenneth Paulus, who had been serving as the Chair of the Compensation Committee and the Chair and financial expert of the Audit Committee, agreed to resign as a director of the Company effective as of May 24, 2016 and the remaining members of the Board agreed to use best efforts to, within 60 days of the effectiveness of such resignations, nominate and elect as directors two (2) outside, independent directors who are qualified under the Company’s governing documents and policy, including one director to be qualified under NASDAQ Rule 5605(c)(2) as a financial expert, and (v) the parties to the Settlement agreed to certain mutual release of claims relating to or arising out of the governance and management of the Company, the proxy contest and/or other matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time.as issue in the related litigation.
 
ITEM 1A.RISK FACTORS

We are a smaller reporting company and are not required to provide the information required by this Item.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Upon exercise of stock options or vesting of restricted stock, employees can request the company to withhold shares to pay the resulting income tax withholdings of the employee.  These transactions constitute stock repurchases and are the only stock repurchases engaged in by the Company.  Information regarding the Company’s stock repurchasesrepurchase during the three months ended SeptemberJune 30, 20152016 is as follows:

Period 
Total
Number of
Shares
Purchased(a)
  
Average Price
Paid per
Share
  
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
  
Maximum Number of
Shares that May Yet
Be Purchased Under
the Plans or Programs
 
July 1, 2015 – July 31, 2015  -   -   -   - 
August 1, 2015 – August 31, 2015  9,489   1.66         
September  1, 2015 – September 30, 2015  -   -   -   - 
                 
Total  9,489  $1.66   -   - 
Period 
Total
Number of
Shares
Purchased(a)
  
Average Price
Paid per
Share
  
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
  
Maximum Number of
Shares that May Yet
 Be Purchased Under
the Plans or Programs
 
April 1, 2016 – April 30, 2016  54,468  $1.05   -   - 
May1, 2016 – May 31, 2016  -   -         
June  1, 2016 – June 30, 2015  730   1.02   -   - 
                 
Total  55,198  $1.04   -   - 

(a)Represent shares surrendered to cover tax obligation for restricted stock vested.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5.OTHER INFORMATION

None.

ITEM 6.EXHIBITS

Exhibits

Exhibit
No.
 Exhibit Method of Filing
*2.1 Agreement and Plan of Merger dated as of December 21, 2014 by and among Vision-Sciences, Inc., Visor Merger Sub LLC, and Uroplasty, Inc. Incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K as filed with the SEC on December 22, 2014 (File No. 000-20970)
     
3.1 (a) Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended March 31, 2001 (File No. 000-20970)
     
  (b) Certificate of Amendment to Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended March 31, 2001 (File No. 000-20970)
     
  (c) Certificate of Amendment to Certificate of Incorporation. Incorporated by reference to Exhibit 99.2 to Current Report on Form 8-K as filed with the SEC on December 15, 2010 (File No. 000-20970)
     
  (d) Certificate of Amendment to Certificate of Incorporation. Incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K as filed with the SEC on August 1, 2014 (File No. 000-20970)
 
  (e) Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K as filed with the SEC on March 31, 2015 (File No. 000-20970)
     
  (f) Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K as filed with the SEC on March 31, 2015 (File No. 000-20970)
     
3.2 Amended and Restated Bylaws.Bylaws, as Amended. Incorporated by reference to Exhibit 99.23.2 to CurrentQuarterly Report on Form 8-K10-Q as filed with the SEC on July15, 2009May 16, 2016 (File No. 000-20970).
     
10.1 Loan Agreement, made as of September 18, 2015, by and among Cogentix Medical, Inc., Machida Incorporated, Uroplasty, LLC and Venture Bank Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K as filed with the SEC on September 21, 2015 (file No. 000-20870)
     
31.1
 Certification by the CEOPEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith
     
31.2
 Certification by the CFOPFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith
     
32.1
 Certification by the CEOPEO pursuant to Section 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Filed herewith
     
32.2
 Certification by the CFOPFO pursuant to Section 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Filed herewith

101.INS XBRL Instance Furnished herewith **
     
101.SCH XBRL Taxonomy Extension Schema Furnished herewith **
     
101.CAL XBRL Taxonomy Extension Calculation Furnished herewith **
     
101.DEF XBRL Taxonomy Extension Definition Furnished herewith **
     
101.LAB XBRL Taxonomy Extension Labels Furnished herewith **
     
101.PRE XBRL Taxonomy Extension Presentation Furnished herewith **


* Certain schedules to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K.  We will furnish copies of any such omitted schedules to the SEC upon request.

** XBRL information is furnished and not filed or a part
Page 28
SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 COGENTIX MEDICAL, INC.
  
Date: November 12, 2015
By: /s/ ROBERT KILL
 Robert KillDate:
August 15, 2016 President, Chief Executive Officer and Chairman of the Board
By:(Principal executive officer)
/s/ DARIN HAMMERS
  
Date: November 12, 2015
By: /s/ BRETT REYNOLDSDarin Hammers
President and Chief Executive Officer
(Principal Executive Officer)
 Brett ReynoldsDate:August 15, 2016By:/s/ BRET REYNOLDS
 
Brett Reynolds
Senior Vice President, Chief Financial Officer and Corporate Secretary
(Principal financialFinancial and accounting officer)Accounting Officer)
 
 
Page 2729